Plain-English translation of NCT07217067 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Atrial Fibrillation research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new medication called to see if it can help reduce how often and how long people experience atrial fibrillation—a condition where the heart's upper chambers beat irregularly. Researchers want to understand whether this medication is safe, well-tolerated, and effective at reducing the amount of time participants spend in this abnormal rhythm. About 165 people will participate, with some receiving the medication and others receiving a placebo (a pill with no active ingredient) to compare results fairly.
Atrial fibrillation affects millions of people and can increase the risk of stroke and other heart problems. Currently available treatments don't work well enough for everyone, so researchers are testing this medication to see if it offers a better option for controlling the irregular heartbeats.
You likely qualify if…
You likely don't qualify if…
You will have a screening period of up to 90 days to confirm you're eligible for the study. Once enrolled, you'll be randomly assigned to take either the new medication, a higher dose of the medication, or a placebo by mouth daily. Over 24 weeks, you'll visit the clinic about once a month, and your heart rhythm will be monitored using various ECG devices (including heart monitors you may wear at home). About one month after the treatment ends, you'll have a final safety check-up visit.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
United States